Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation
Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation
"We founded Bambusa Therapeutics with a belief that the I&I field is long overdue for innovative approaches and transformative therapeutics. Since our inception, we have built a diverse portfolio of molecules and is uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions," said Dr. BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately $15 million.
波士顿，2024年9月9日 /PRNewswire/ — 专注于开发用于治疗免疫和炎症（I&I）疾病的双特异性抗体的生物技术公司Bambusa Therapeutics Inc. 宣布成功完成其系列种子轮融资，筹集了约1500万美元。
Bambusa Therapeutics was founded by a team of industry experts and scientific innovators united by a vision to transform the treatment landscape for I&I diseases. The company leverages validated targets to create bispecific antibody therapeutics through innovative antibody engineering, with an aim to achieve best-in-disease profiles for multiple indications.
Bambusa Therapeutics由一支由行业专家和科学创新者组成的团队创立，他们的愿景是改变I&I疾病的治疗格局。该公司利用经过验证的靶点，通过创新的抗体工程开发双特异性抗体疗法，旨在为多种适应症实现最佳病情特征。
The financing round was co-led by BVF Partners L.P. and Dawn Biopharma, a platform controlled by KKR, with participation from Salvia GmbH and INCE Capital. The capital raised will be used to accelerate the development of Bambusa Therapeutics Inc.'s promising pipeline of bispecific antibodies to Phase I clinical studies.
本轮融资由BVF Partners L.P. 和由KKR控制的平台Dawn Biopharma共同牵头，Salvia GmbH和INCE Capital也参与其中。筹集的资金将用于加速Bambusa Therapeutics Inc.的发展。”具有前景的I期临床研究双特异性抗体产品线。
"We founded Bambusa Therapeutics with a belief that the I&I field is long overdue for innovative approaches and transformative therapeutics. Since our inception, we have built a diverse portfolio of molecules and is uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions," said Dr. Shanshan Xu, CEO and Co-Founder of Bambusa Therapeutics.
“我们创立Bambusa Therapeutics时坚信创新方法和变革性疗法早就该进入I&I领域了。Bambusa Therapeutics首席执行官兼联合创始人徐珊珊博士说，自成立以来，我们已经建立了多元化的分子组合，处于独特的地位，可以为患有虚弱性和慢性炎症的患者做出重大贡献。
Helmut Jeggle, Managing Director of Salvia GmbH and Co-Founder of Bambusa Therapeutics, commented, "We are thrilled to have the support of such distinguished investors who share our vision. This funding will allow us to strengthen the team to advance our lead candidates through preclinical development and position us for success in clinical studies."
Salvia GmbH董事总经理兼Bambusa Therapeutics联合创始人赫尔穆特·杰格尔评论说：“我们很高兴得到这些与我们有着共同愿景的杰出投资者的支持。这笔资金将使我们能够加强团队，通过临床前开发推动我们的主要候选人发展，并为我们在临床研究中取得成功做好准备。”
About Bambusa Therapeutics Inc.:
关于 Bambusa Therapeutics Inc.：
Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, our mission is to advance the field of immunology with cutting-edge solutions.
Bambusa Therapeutics是一家快速发展的生物技术公司，专门开发变革性的炎症和免疫疗法。我们的总部设在充满活力的波士顿海港地区，我们的使命是通过尖端解决方案推动免疫学领域的发展。
SOURCE Bambusa Therapeutics
来源 Bambusa Therapeutics
